Hormone receptor (HR)-positive, HER2-negative early-stage breast cancer

Hormone receptor (HR)-positive, HER2-negative early-stage breast cancer is a localized malignancy of the mammary epithelium characterized by the expression of estrogen and/or progesterone receptors without overexpression or amplification of the human epidermal growth factor receptor 2 protein

Hormone receptor (HR)-positive, HER2-negative early-stage breast cancer is a localized malignancy of the mammary epithelium characterized by the expression of estrogen and/or progesterone receptors without overexpression or amplification of the human epidermal growth factor receptor 2 protein Representing the most prevalent subtype of breast cancer, it typically affects adult female breast tissue, though it can also occur in males Pathophysiologically, tumor cell proliferation is primarily drive...

Representing the most prevalent subtype of breast cancer, it typically affects adult female breast tissue, though it can also occur in males

Pathophysiologically, tumor cell proliferation is primarily driven by hormone-receptor signaling pathways while remaining confined to the breast and regional lymph nodes (stages I through III) without distant metastatic spread Although generally characterized by favorable initial prognoses, this clinical subtype retains a persistent risk of late locoregional or distant recurrence over decades, often influenced by tumor grade, nodal burden, and genomic risk profiles

Pathophysiologically, tumor cell proliferation is primarily driven by hormone-receptor signaling pathways while remaining confined to the breast and regional lymph nodes (stages I through III) without distant metastatic spread

Although generally characterized by favorable initial prognoses, this clinical subtype retains a persistent risk of late locoregional or distant recurrence over decades, often influenced by tumor grade, nodal burden, and genomic risk profiles

Although generally characterized by favorable initial prognoses, this clinical subtype retains a persistent risk of late locoregional or distant recurrence over decades, often influenced by tumor grade, nodal burden, and genomic risk profiles